NEW YORK — Mylan Pharmaceuticals Inc., Breckenridge Pharmaceutical Inc. and APP Pharmaceuticals have received approval from the Food and Drug Administration to offer anastrozole tablets, a treatment for early breast cancer.
The companies said Tuesday they plan to market 1 mg anastrozole tablets. The medication is the generic version of AstraZeneca’s Arimidex tablets.
Citing IMS Health data, Mylan reported that anastrozole tablets has U.S. sales of about $917 million for the 12 months ended March 31. APP Pharmaceuticals said the drug had 2009 sales of approximately $916.8 million, with about 105 million tablets sold annually, according to IMS data.
All three companies said they plan to make the anastrozole tablets available immediately.
Comments are closed.